TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH OESTROGENS AND ANDROGENS

1960 ◽  
Vol XXXIV (I) ◽  
pp. 51-59 ◽  
Author(s):  
C. A. Hernberg
Keyword(s):  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
Age Group ◽  
Intermittent Treatment ◽  
Considerable Loss

ABSTRACT Fifteen patients with postmenopausal osteoporosis and 51 postmenopausal women without osteoporosis were subjected to intermittent treatment with oestrogens and androgens during 2 to 8 years. In the patients with osteoporosis there was prior to treatment a considerable loss of height which ceased more or less during therapy. In the nonosteoporotic postmenopausal women there was a negligible reduction in height during treatment in comparison to control cases of the same age group.

Experimental techniques for screening of antiosteoporotic activity in postmenopausal osteoporosis

2015 ◽  
Vol 12 (4) ◽  
Author(s):  
Swaha Satpathy ◽  
Arjun Patra ◽  
Bharti Ahirwar
Keyword(s):  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
Health Hazard ◽  
Low Bone Mass ◽  
Major Health ◽  
Prevent Bone Loss ◽  
Increased Risk ◽  
Tnf Α ◽  
Necrosis Factor ◽  
Ovariectomized Animal

AbstractPostmenopausal osteoporosis, a silent epidemic, has become a major health hazard, afflicting about 50% of postmenopausal women worldwide and is thought to be a disease with one of the highest incidences in senile people. It is a chronic, progressive condition associated with micro-architectural deterioration of bone tissue that results in low bone mass, decreased bone strength that predisposes to an increased risk of fracture. Women are more likely to develop osteoporosis than men due to reduction in estrogen during menopause which leads to decline in bone formation and increase in bone resorption activity. Estrogen is able to suppress the production of proinflammatory cytokines like interleukin (IL)-1, IL-6, IL-7 and tumor necrosis factor (TNF-α). This is why these cytokines are elevated in postmenopausal women. In this review article we have made an attempt to collate the various methods and parameters most frequently used for screening of antiosteoporotic activity in postmenopausal osteoporosis. Pertaining to ovariectomized animal model, this is the most appropriate model for studying the efficacy of different drugs to prevent bone loss in postmenopausal osteoporosis.

Evaluation of zygomatic bone region for placement of quad zygomatic implants using CBCT in postmenopausal women

2021 ◽  
Vol 7 (2) ◽  
pp. 48-53
Author(s):  
Neelam Manoj Vaibhav ◽  
Ramesh Amirisetty ◽  
Rajesh Nichenametla ◽  
Gonabhavi Siri Chandana ◽  
Santhi Prathyusha M ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Bone Volume ◽  
Primary Osteoporosis ◽  
Alveolar Ridge ◽  
Age Group ◽  
Zygomatic Bone ◽  
Zygomatic Implants ◽  
Bone To Implant Contact

Insufficient height and width of the alveolar ridge at the implant site remains with inadequate bone volume following extraction in older age people especially in postmenopausal women. Postmenopausal women are susceptible to primary osteoporosis where more bone resorption than formation is seen resulting in decreased bone mass. Hence the present study aims to evaluate the zygomatic bone region for placement of quad zygomatic implants using CBCT.: A total of 120 CBCT images of female patients who were between the age group of 45 yrs to 65 yrs were taken. The zygomatic bone was evaluated for pneumatisation zones and thickness of zygomatic bone at three different regions i.e., superior, middle and inferior at nine points on zygoma bone along with bone to implant contact (BIC) region using virtual software. The largest thickness in the superior, middle and inferior regions were at Point A2(8.01+/-2.10 mm), Point B2 (7.01+/-1.62 mm), and Point C1 (6.65+/-1.64 mm), respectively. The virtually placed implants at Point A3 (15.92+/-4.16 mm) and Point B2 (12.02+/-3.62 mm) had the highest BICs. : To obtain the largest BICs, results suggested that the posterosuperior region (Point A3) and the centre of zygoma (Point B1) were the optimal places for the placement of quad zygomatic implants.

scholarly journals Ubiquitylomes Analysis of the Whole blood in Postmenopausal Osteoporosis Patients and healthy Postmenopausal Women

2019 ◽  
Vol 11 (6) ◽  
pp. 1187-1200
Author(s):  
Yi‐ran Yang ◽  
Chun‐wen Li ◽  
Jun‐hua Wang ◽  
Xiao‐sheng Huang ◽  
Yi‐feng Yuan ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
Whole Blood

scholarly journals Sclareol prevents ovariectomy-induced bone loss in vivo and inhibits osteoclastogenesis in vitro via suppressing NF-κB and MAPK/ERK signaling pathways

2019 ◽  
Vol 10 (10) ◽  
pp. 6556-6567 ◽  
Author(s):  
Haiming Jin ◽  
Zhenxuan Shao ◽  
Qingqing Wang ◽  
Jiansen Miao ◽  
Xueqin Bai ◽  
...  
Keyword(s):  
Bone Loss ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
Bone Quality ◽  
Progressive Disease ◽  
Erk Signaling ◽  
Low Bone Mass

Postmenopausal osteoporosis (PMO) is a progressive disease occurring in elderly postmenopausal women that is characterized by low bone mass and impaired bone quality.

scholarly journals Effects of Tibolone on Markers of Bone Metabolic Activity in Postmenopausal Women

2012 ◽  
Vol 31 (2) ◽  
pp. 121-125
Author(s):  
Snežana Krejović ◽  
Aleksandar Živanović ◽  
Sandra Živanović ◽  
Rade Marković
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
Metabolic Activity ◽  
Systemic Disease ◽  
Economic Problem ◽  
Control Group ◽  
Bone Mass Loss ◽  
Average Value

Effects of Tibolone on Markers of Bone Metabolic Activity in Postmenopausal WomenOsteoporosis, a systemic disease of the bones, is a serious health and socio-economic problem because of its consequences, i.e. broken bones. It is believed that 10% of the world's population suffers from osteoporosis and it affects mostly postmenopausal women (postmenopausal osteoporosis). Tibolone is a synthetic steroid that has estrogenic, androgenic, and progestagenic properties. It has been used primarily for the prevention of postmenopausal osteoporosis and treatment of climacteric symptoms. The research included a group of 40 postmenopausal women with osteopenia treated with tibolone. The control group included 40 postmenopausal women who were not taking any medication. Control group patients were older (54.5 ± 9.84) than the patients treated with tibolone (51.6 ± 6.22). Bone metabolic activity was evaluated using osteocalcin (N-MID osteocalcin) for bone formation and CTX I for bone resorption. Blood samples were taken before therapy was introduced and 3 months after its introduction. The average value of osteocalcin after three months of tibolone therapy was 26.32 ± 3.312 ng/mL compared to the average osteocalcin value prior to therapy of 29.6 ± 3.343 ng/mL. The average value of CTX I three months after tibolone therapy of 0.2870 ± 0.0783 ng/mL was lower compared to the average CTX I value before the therapy of 0.4539 ± 0.1144 ng/mL. Our results show the efficacy of tibolone in preventing bone loss, which was highly statistically significant. They also reveal its suppressive effects on bone formation and resorption, but these effects are statistically less significant. Tibolone significantly reduces the level of bone resorption in postmenopausal women with osteopenia. Its effects on bone formation are less expressed. The parameters of bone metabolic activity are a very useful diagnostic means in the evaluation of tibolone effects on bone metabolic activity and in the prognosis of bone mass loss.

scholarly journals Serumβ-Catenin Levels Associated with the Ratio of RANKL/OPG in Patients with Postmenopausal Osteoporosis

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Xiao-Juan Xu ◽  
Lin Shen ◽  
Yan-Ping Yang ◽  
Rui Zhu ◽  
Bo Shuai ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
Bone Turnover Markers ◽  
Enzyme Linked Immunosorbent Assay ◽  
Functional Communication ◽  
Mineral Density ◽  
Wnt Pathways ◽  
Turnover Markers

Objective. To demonstrate the role of Wnt/β-catenin canonical pathway in postmenopausal osteoporosis by evaluating serumβ-catenin levels in patients with postmenopausal osteoporosis and analyzing their possible relationship with serum OPG, RANKL, the ratio of RANKL/OPG, sclerostin, and bone turnover markers.Methods. 480 patients with postmenopausal osteoporosis and 170 healthy postmenopausal women were enrolled in the study. Serumβ-catenin, OPG, RANKL, and sclerostin levels were measured by enzyme-linked immunosorbent assay. Bone status was assessed by measuring bone mineral density and bone turnover markers. Estradiol levels were also detected.Results. Serumβ-catenin levels were lower in postmenopausal osteoporotic women compared to nonosteoporotic postmenopausal women (26.26±14.81versus39.33±5.47 pg/mL,P<0.001). Serumβ-catenin was positively correlated with osteoprotegerin (r=0.232,P<0.001) and negatively correlated with the ratio of RANKL/OPG, body mass index, and sclerostin (r=-0.128,P=0.005;r=-0.117,P=0.010;r=-0.400,P<0.001, resp.) in patients with postmenopausal osteoporosis.Conclusion. The results indicate that lower serumβ-catenin and concomitantly higher ratio of RANKL/OPG may be involved in the pathogenesis of postmenopausal osteoporosis. Functional communication between RANKL/RANK/OPG system and Wnt pathways plays an important role in postmenopausal osteoporosis.

Association Between Serum Ferritin Levels and Low Bone Mineral Density in Postmenopausal Osteoporosis Women

2020 ◽  
Author(s):  
Lama ALjeshi ◽  
Shaden Haddad
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
Bone Mineral ◽  
Serum Ferritin ◽  
Serum Ferritin Level ◽  
Ferritin Level ◽  
Mineral Density ◽  
Low Bone Mineral Density ◽  
Femur Neck

As women go through menopause, serum estrogen decreases, and ferritin increases. Ferritin is an essential component of the body, but many studies have stated that ferritin, which exceeds the normal physiological range, may potentially cause health problems in women. The aim of this study is to investigate the relationship between bone mineral density and serum ferritin levels in post-menopausal women and to evaluate serum ferritin levels as a potential biomarker for postmenopausal osteoporosis. Serum ferritin levels were measured in 62 postmenopausal women with low bone mineral density, and in 18 postmenopausal healthy control women using a standardized Enzyme-Linked Immune Sorbent Assay (ELISA) kit. Bone mineral density BMD was assessed at the lumbar spine and femoral neck. The mean serum ferritin level was significantly higher in the postmenopausal women with low BMD group (group 1) than in the normal control group (group 2), respectively (mean=262.69 vs. 181.44 ng/ml, (P<0.05), and serum ferritin level was negatively correlated with BMD among low BMD postmenopausal women's group (R= -0.628, P=0.0001), and in the healthy postmenopausal group (R= -0.052, P=0.838). A comparison of the BMD between spine and femur neck sites shows that the frequency of low BMD in the spine site is higher than the femur neck site. Our findings show that increased serum ferritin levels were associated with low bone mineral density in postmenopausal osteoporosis.

scholarly journals Overall adjustment acupuncture for postmenopausal osteoporosis (PMOP): A study protocol for a randomized sham-controlled trial

2020 ◽  
Author(s):  
ZQ ren ◽  
YF Wang ◽  
GF Ao ◽  
HX Chen ◽  
M Huang ◽  
...  
Keyword(s):  
Side Effects ◽  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
Acupuncture Treatment ◽  
Bone Marrow Cells ◽  
Controlled Trial ◽  
Osteoporotic Fractures ◽  
Pain Scale ◽  
Mineral Density ◽  
Clinical Trial Registry

Abstract Background: Osteoporosis is becoming more prevalent in aging societies worldwide, and the economic burden attributable to osteoporotic fractures is substantial. The medications presently available to treat osteoporosis have side effects, acupuncture is widely used for the postmenopausal women because of it is non-invasive and has fewer side effects, but the powerful evidence for the clinic is still insufficient. Our study intends to explore the effect of Overall adjustment acupuncture (OA) in the treatment of postmenopausal osteoporosis(PMOP).Methods: This study is a randomized, sham-controlled, patient-and assessor-blinded trial and aims to evaluate the effect of OA in women with PMOP. We will recruit 104 women aged 45-70 years with a diagnosis of PMOP. Participants will be randomly allocated in a 1:1 ratio to the OA group and the sham acupuncture (SA) group. Both groups will receive real herbal medicine treatment as a basic treatment twice a day for three months, the OA group receive real acupuncture treatment and the SA group received placebo acupuncture treatment (non-penetrating,sham skin needle therapy, sham cupping). All patients will receive acupuncture treatment twice per week for three months. The primary outcome is bone mineral density(BMD) and secondary outcomes include estradiol(E2), follicle-stimulating hormone(FSH), bone gla protein(BGP), bone alkaline phosphatase (BALP), total antioxidant capacity(TAC), advanced oxidation protein products(AOPP) ,PPARγ, β-Catenin,FoxO3a, visual pain scale score(VAS) , Traditional Chinese Medicine (TCM) syndrome scores and quality of daily life score(QOL). Outcome measures will be collected at baseline, middle of the treatment(1.5 months), the end of treatments(3month).The present protocol followed the SPIRIT guidelines and fulfilled the SPIRIT checklist.Conclusion: This study will be conducted to compare the efficacy of OA versus SA. This trial will help to evaluate whether OA can effectively prevent and treat postmenopausal osteoporosis by improving the estrogen level of postmenopausal women, the mechanism is to improve the imbalance of osteogenic differentiation and lipogenesis of bone marrow cells under oxidative stress.Trial registration: This trial was registed at Chinese Clinical Trial Registry, registration date: 5 August 2018.URL:http://www.chictr.org.cn,registration number:ChiCTR1800017581.

scholarly journals Do we use methylation of NFATC1 and FOS genes as a biomarker for postmenopausal osteoporosis?

2020 ◽  
Vol 23 (2) ◽  
pp. 35-40
Author(s):  
R Kalkan ◽  
O Tosun
Keyword(s):  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
High Resolution Melting ◽  
Methylation Status ◽  
Premenopausal Women ◽  
Epigenetic Factors ◽  
Receptor Activator ◽  
Postmenopausal Status ◽  
First Time ◽  
Nuclear Factor Κ B

Abstract Genetic and epigenetic factors have an important role during the development of osteoporosis. Receptor activator of nuclear factor-κ B (NF-κB) (RANK)/receptor activator of NF-κB ligand (RANKL) pathway is important for the bone remodeling, and NFATC1 and FOS are the downtargets of this pathway. Here, we report methylation status of NFATC1 and FOS genes in post- and premenopausal women. In this study, 30 premenopausal and 35 postmenopausal women were included. Methylation sensitive-high resolution melting (MS-HRM) analysis was used for identification of NFATC1 and FOS genes methylation. The NFATC1 gene was methylated in 11 of the 35 postmenopausal women, and the FOS gene was methylated in six of the postmenopausal women (p >0.005). Here, we found statistically significant association between unmethylation of the NFATC1 gene and postmenopausal status. This result explains the epigenetic regulation of osteoclasts during the menopausal transition, and for the first time, our results can be used for epigenetic explanation of postmenopausal osteoporosis in the literature. However, the limited number of studies in this field makes our results crucial. Our results showed great value of epigenetic profiles of postmenopausal women.

Sign in / Sign up

Export Citation Format

Share Document